Eli Lilly has raised its revenue guidance ... In its update, Ricks said a new facility at Concord in North Carolina – part of an $18 billion investment programme launched in 2020 – is being ...

North Carolina checks all the boxes from the standpoint ... I was on the same flight back with his parents and his sister (Lilly). They were on a visit to Duke, so I was talking to them a little ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

FILE - A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis on April 26, 2017. (AP Photo/Darron Cummings, File) Eli Lilly’s profit doubled in the fourth ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 116 trades. If we consider the specifics of each ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Eli Lilly Mounjaro Zepbound GLP-1 Lilly on Thursday reported fourth-quarter revenue of $13.53 billion, a steep 45% increase over the sum the Indianapolis-based drugmaker generated during the same ...